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In  an attempt to isolate new G protein-coupled recep- 
tors from turkey erythrocytes, reverse transcribed po- 
lymerase chain reaction was performed on fetal  turkey 
blood RNA using degenerate primers based on con- 
served sequences present in seven transmembrane re- 
ceptors. An open reading frame in one of the clones, 
designated 4C (497 base pairs), displayed approximately 
5040% identity  to all of the previously cloned P-adre- 
nergic receptors ( P A R S ) .  A A-DASH turkey genomic li- 
brary was screened with a probe generated from the 
partial 4C cDNA, and  the gene encoding this  receptor 
was localized to a 3.5-kilobase pair HindZII fragment. 
Ribonuclease protection analysis of turkey  lung mRNA 
indicated that  the 3’ end of the coding sequence of the 
4C gene, like p,-AFt, was interrupted by an intron. To 
obtain the cDNA sequence of 4C, RNA-polymerase chain 
reaction was performed using primers complementary 
to regions identified by ribonuclease protection analysis 
to be present in 4C mRNA. Comparison of the genomic 
and cDNA sequences of 4C indicated that  the first exon 
encodes 414 amino acids of the protein, the second exon 
(68 base pairs) encodes an additional 12 residues fol- 
lowed  by a stop codon, and  the  third exon is composed of 
3’-untranslated sequence. The 4C receptor was tran- 
siently expressed in COS-1 cells, and  the  apparent affini- 
ties of a series of P - A R  agonists and  antagonists were 
determined using [‘261]iodocyanopindolol. As implicated 
by its amino acid sequence, 4C displayed a pharmaco- 
logical selectivity that was consistent with that of a 
P-AFt but  distinct from other cloned /?-A&. Isoproter- 
enol, epinephrine,  and  norepinephrine stimulated cy- 
clic AMP accumulation in a concentration-dependent 
manner  in mouse L cells stably expressing the 4C recep- 
tor. No effect  on phospholipase C activity was  observed. 
Ribonuclease protection assays indicated that 4C mRNA 
exhibits a broad tissue distribution, which suggests that 
it may  play an important role in avian physiology. 
p-ARs’ were originally divided into two  subtypes, p,-AR and 
p,-AR, based on the  relative potencies of the agonists isopro- 
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and @,-AR, P I - ,  &-, and @,-adrenergic receptors, respectively; P,-AR,  
The abbreviations used are: @-AFt, @-adrenergic receptor; &, &-, 
turkey  erythrocyte  P-adrenergic receptor; ICYF’, (-)-iodocyanopindolol; 
terenol,  epinephrine, and norepinephrine (1) and, subse- 
quently, on the selectivity of several p-AR antagonists. The 
existence of multiple p - A R  subtypes was verified by isolation of 
c D N h  encoding &-AR and &-AR (2, 3). The two receptors 
showed 54% similarity in their amino acid sequences, which 
increased to 71% when only the regions in  the  putative  trans- 
membrane  segments were compared (2). An unexpected finding 
from this work was that both the p,-AR and &-AR genes lack 
introns (4-61, which appears  to  be a feature conserved in  many 
other, but  not all,  members of the G protein-coupled receptor 
superfamily (7-11). 
The existence of additional  p-adrenergic  receptors  was sug- 
gested from studies in which various  catecholamine-promoted 
metabolic processes in  the digestive tract, adipose tissue,  heart, 
and  skeletal muscle were shown to be insensitive to classical 
p-adrenergic receptor antagonists (12-14). Synthetic p-adre- 
nergic  receptor  agonists were identified that  stimulated  many 
of these metabolic processes, but showed minimal  activity at P I -  
or p,-ARs (15). Recently, Emorine et  al .  (16) reported the clon- 
ing from a human genomic library of a third @-AR subtype, 
& A R ,  which displayed about 50% amino acid identity with 
&-AR and &-AR (17). &-AR from rat (17) and mouse (18) 
subsequently were cloned, and comparison of genomic and 
cDNA sequences  revealed the presence of an  intron (19, 20). 
The  first exon encodes the majority of the protein, whereas  the 
second exon encodes only the  last several  amino  acids at  the 
carboxyl terminus.  The coding sequence of the  human p,-AR 
gene is also interrupted by an  intron,  although  the genomic 
organization of the  human gene differs significantly from the 
rat gene (19, 21). 
The pharmacological selectivities of the expressed human 
and rat &-AR were different  from  those of &-AR and & A R ,  
and mimicked at least  part of the “atypical” @-AR drug selec- 
tivities observed in several tissues (16, 17, 22). Whether the 
&-AR is responsible for all of the effects elicited by atypical 
p-adrenergic  agonists is not clear. For  example, the  apparent 
tissue  distribution of rat &-AR mRNA, which is found largely 
in adipose tissue  and  to a  small extent  in ileum, does not  match 
the  tissue distribution of the atypical  responses (23). Thus,  the 
full complement of mammalian p-adrenergic  receptor subtypes 
may not yet be realized. 
An additional 0-AR expressed on turkey erythrocytes has 
been studied extensively (24-26). This receptor, designated p,- 
AR, was  initially classified as  the  turkey homologue of mam- 
malian p,-AR based on its approximately equal affinities for 
epinephrine  and norepinephrine. The gene for &-AR has been 
cloned from a fetal  turkey blood  cDNA library, and  its deduced 
amino acid sequence is between 38-59% homologous to the 
sequences of the  mammalian p-AR subtypes. 0,-AR displays 
highest homology (59%) to  mammalian p,-AR, but  apparently 
bp, base pair; kb, kilobase pair; IBMX, 3-isobutyl-1-methylxanthine; 
PCR, polymerase chain reaction. 
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does not  represent  an  avian homologue of the p,-AR. This  de- 
gree of homology would be very low for species homologues, 
even given the  large evolutionary distance between birds  and 
mammals,  and &-AR has a unique pharmacological selectivity 
that does not match  the selectivity of either  mammalian &-AR 
or &-AR (25, 27). Furthermore, unlike mammalian P A R S ,  
&-AR does not  internalize upon agonist  stimulation  and dis- 
plays only a low affinity  agonist binding  state  that  is  insensi- 
tive to  guanine nucleotides (2'7,281. No mammalian homologue 
of p,-AR has been identified. 
Members of the broad family of G protein-coupled receptors 
share considerable homology within  their seven putative  trans- 
membrane domains. Libert et al. (29) designed a pair of degen- 
erate oligonucleotides based on the conserved amino acid (and 
nucleotide) sequences in the third and sixth putative trans- 
membrane regions to successfully amplify by PCR several novel 
G protein-coupled receptor cDNAs. We adopted  a similar  strat- 
egy to  isolate  several novel G protein-coupled receptors from 
fetal  turkey erythrocyte RNA. Among five distinct cDNAs with 
homology to G protein-coupled receptors that were  isolated, one 
clone (4C) displayed 50-60% homology within the amplified 
region to  p - M s .  This homology was within  the  range calcu- 
lated among  each of the  mammalian 6-AR subtypes. Thus, 4C 
appeared  to encode a novel p-AR. In  this  report we describe the 
cloning, sequencing, and genomic organization of the 4C recep- 
tor. The receptor cDNA was expressed in COS-1 and mouse L 
cells and its pharmacological selectivity and regulation of sec- 
ond messenger signaling were examined. Results from these 
studies,  together  with  those showing a broad tissue  distribu- 
tion, indicate  that 4C encodes a novel p-AR that may  play an 
important role in  avian physiology. 
EXPERIMENTAL PROCEDURES 
Materials-Mouse L  cells  and  tissue  culture  reagents  were f om the 
tissue culture facility in the Lineberger Cancer Research Center a t  
UNC-CH. COS-1  cells  were  kindly  provided by Dr. Ellen Weiss, Dept. of 
Cell Biology, UNC-CH. NalZSI  was from Amersham Corp. 8-E3H1Adenine 
and 2-[3Hlmyoinositol were  obtained  from  American  Radiolabeled 
Chemicals  (St.  Louis, MO). G418 sulfate  was  purchased from Life Tech- 
nologies, Inc. Acebutolol, celiprolol, (-)-cyanopindolol, IC1 89406, IC1 
118551, metoprolol,  and  sotalol  were  kindly provided by  Dr.  P. Molinoff, 
University of Pennsylvania. All other p-AR ligands were purchased 
from Sigma. 
Amplification by PCR of G Protein-coupled Receptor cDNAs-Fetal 
turkey blood total RNA was  isolated  as  described  previously  (30). Total 
RNA (1 pg) was reverse transcribed with dT,, and M-MLV reverse 
transcriptase  using  the  Perkin-Elmer GeneAmp RNA kit. Two degen- 
erate oligonucleotides designed by Libert  et al. (29),  designated TM 111 
and TM VI, were  used to  amplify  G  protein-coupled  receptor cDNAs. 
The  conditions for PCR  amplification  were  94 "C, 45 s; 52 "C, 1 min;  and 
72 "C, 2  min, for 30 cycles. Following the  initial  amplification, an addi- 
tional  30 cycles of PCR were  performed  using 10% of the  initial PCR 
mixture.  The  resulting PCR products  were  digested  with  Sal1  and Hin- 
dIII  (restriction  sites at  the 5' ends of the TM I11 and TM  VI primers, 
respectively),  purified  on an  agarose gel, and subcloned into  pBluescript 
11. Twenty-four  random  clones  were  isolated  and  sequenced,  and five 
distinct  groups of G  protein-coupled  receptor cDNAs were  obtained. 
Construction and  Screening of a nrkey  Genomic Library-Turkey 
genomic DNA was  partially  digested by MboI and size-selected on a 
sucrose  gradient  (31).  The  fractions  containing  DNAfragments  between 
10-40  kb  were combined, dephosphorylated  using calf alkaline phos- 
phatase,  and  ligated to  BamHI-digested A-DASH I1 (Stratagene).  The 
ligation products were packaged in vitro using the Gigapack I1 XL 
packaging kit (Stratagene), which preferentially  packages  phage DNA 
containing inserts between 18 and 23 kb. The library had 1 x lo6 
independent  recombinants  and  was  amplified to  2 x 10" plaque-forming 
units.  A  portion of the genomic library (1 x lo6 phage)  was  plated at a 
density of 5 x lo4 plaques/l50-mm  plate  and  the  plaques  were  trans- 
ferred to  nylon membranes  using  the  method of Benton  and  Davis  (32). 
The  filters  were  prehybridized at  room temperature for 30  min  in  6 x 
SSC, 1 x Denhardt's  solution,  and  hybridized at  42 "C overnight in 50% 
formamide, 6 x SSC, 1 x Denhardt's solution, 0.1 mg/ml fish sperm 
DNA, and  32P-labeled 4C DNA probe (1 x lo7 cpm).  The  radiolabeled 
probe was  generated by random  priming of the 497-bp 4C PCR frag- 
ment using [ C X - ~ ~ P I ~ C T P  and the Pharmacia LKB oligo labeling kit. 
Following hybridization, the  filters  were  washed a t  55 "C with  2 x SSC, 
0.1% SDS,  and  then with 0.1 x SSC, 0.1% SDS.  Filters  were exposed to 
Fuji X-AR5 film overnight  with an intensifying  screen.  Over one hun- 
dred positive clones were  identified, and  phage DNA from five of the 
clones was  prepared.  Southern blot analysis of restricted  phage DNA 
identified  a 3.5-kb HindIII  fragment  that  hybridized to the 4C probe in 
4  out of the 5 clones. This  fragment  was subcloned into M13 for se- 
quence analysis, and the entire HindIII fragment was sequenced on 
both  strands  using  the  Sequenase  2.0  sequencing kit (Amersham/U.S. 
Biochemical Corp.). 
Ribonuclease Protection Assays-To determine  the genomic organi- 
zation of 4C,  ribonuclease  protection  assays  were  performed  using  an- 
tisense RNA derived from various  regions of the genomic clone. Orga- 
nization at the 5' end of the gene was established by cloning the 
BamHI-BstEII  fragment  (see Fig. lA) into  pBluescript.  After  lineariz- 
ing  the  construct  with  either  BamHI,  DraI,  or  PuuII, runoff antisense 
transcripts  were  generated  using  T3  RNApolymerase  in  the  presence of 
[CX-~~PICTP.  The  other RNA probes  shown in Fig. lA were  prepared  in  a 
50 pg of turkey  lung  total RNA using  the RPA I1 kit (Ambion) according 
similar  manner.  Ribonuclease  protection  assays  were  performed  with 
to  the vendor's protocol. 
Isolation of 4C cDNA from TLrkey Lung RNA-RNA-PCR was  per- 
formed  with 1 pg of turkey  lung  total  RNAusing  primers  designed from 
sequences at the  3'  end of the genomic clone that were  determined  to be 
present  in 4C mRNAby  ribonuclease  protection  analysis.  The  upstream 
primer  comprised  nucleotides 1763-1784 and  the  downstream  primer 
comprised nucleotides 3108-3125 of the genomic sequence. After 30 
cycles of amplification, the  resulting  cDNAfragment  was subcloned into 
the  SmaI  site of pBluescript I1 and  sequenced.  For  expression  in  mam- 
malian cells, full-length 4C cDNA was cloned into pcDNA3 (Invitrogen), 
an expression vector containing the cytomegalovirus promoter, the 
SV40 origin for high copy number replication in COS cells, and the 
neomycin gene for selection of stably  transfected cell lines. Briefly, the 
NotI-BamHI  fragment  (nucleotides 803-1959) of the genomic clone and 
the BarnHI-ApaI  fragment from the amplified cDNA clone (ApaI  was 
from the pBluescript I1 polylinker)  were  ligated  into pcDNA3 digested 
with Not1 and  ApaI.  The  final  expression vector construct  was  termed 
pcDNA3-4C. 
Northern Blot-Poly(A+) mRNA was  isolated from turkey  lung  tissue 
using  standard  procedures (31). Aliquots (5 and  17.5  pg) of turkey  lung 
mRNA were  submitted  to  electrophoresis on a 1% agarose gel contain- 
ing 0.66 M formaldehyde  (33),  transferred  to  a nylon membrane,  and 
baked a t  80 "C for 2 h. The  membrane  was  prehybridized at  65 "C for 3 
h in 50% formamide, 5 x SSPE, 5 x Denhardt's  solution, 0.25 mgiml fish 
sperm DNA, 0.1% SDS, and  then  hybridized a t  65 "C overnight  in 1 x 
Denhardt's  solution, 0.1 mg/ml fish  sperm DNA, 0.1% SDS, 6 x SSPE 
containing  [~~-~'P]CTP-labeled  antisense 4C  RNA probe (8 x lo7 cpm). 
The probe was  generated as described above for the ribonuclease pro- 
tection  assays.  The blot was  washed at  75 "C in 1 x TE  and exposed to 
film overnight.  The  sizes of the positive bands  were  calculated from the 
migration of RNA standards  run on the  same gel. 
Expression of 4C Receptor in COS-1 and Mouse L Cells-COS-1 cells 
were  maintained  in Dulbecco's modified Eagle's medium  supplemented 
with 10% fetal bovine serum, 20 mM Hepes,  and  penicillidstreptomycin. 
Mouse L cells were  maintained  in  Eagle's  minimal  essential  medium 
supplemented  with 10% fetal bovine serum  and  penicillidstreptomycin. 
All cells were  maintained  in  a  37 "C incubator  under a 5% CO, atmo- 
sphere  and  subcultured  after  reaching confluence (4-6 days).  For tran- 
sient  expression,  either pcDNA3 or  pcDNA34C  was  transfected  into 
COS-1 cells using  the  DEAE-dextraddimethyl sulfoxide shock  method 
(34). For  stable  expression,  actively  growing  mouse  L  cells  were 
trypsinized  and  resuspended  in  Hepes-saline  buffer at  a  density of 1 x 
lo6cells/ml. Cells (0.33  ml)  were  incubated on ice for 5 min  with  7  pg of 
either pcDNA3 or  pcDNA34C  and  then  transfected by electroporation 
at 4 "C (capacitance  25  microfarads, field strength  3 kV/cm). Following 
electroporation, the  mixtures  were  incubated on ice for 10 min  and  then 
plated  in  four  100-mm  tissue  culture  dishes  in  normal  medium. G418 
sulfate  (370  pg/ml)  was  added  to  the  medium  after  48  h,  and  the  me- 
dium containing G418 was replaced every 4-5 days. G418-resistant 
clonal cell lines  were  isolated,  and cells expressing  the 4C receptor  were 
identified by ['ZsIICYF' binding.  Several positive clones expressing dif- 
ferent  levels of the 4C receptor  were  isolated  and  maintained in G418 
medium. 
[*2511CYP Binding A~says-['~~1]CYF' was  synthesized from (-)-cyan- 
opindolol and N a Y  by the chloramine T procedure and purified by 
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FIG. 1. Restriction map of the 3.5-kb 
HindIII  genomic  fragment  a d 
genomic  organization of the 4C gene. 
Panel A shows the restriction  map of the 
3.5-kb HindIII fragment containing the 
4C gene. Starred sites (*I indicate that 
other  restriction  sites  are  present  but  not 
shown. The arrows below the fragment 
indicate  the  antisense RNA constructs 
that were  used  in  ribonuclease  protection 
analyses  to  determine  the genomic orga- 
nization of the 4C gene. Panel B shows 
the intron-exon organization of the 4C 
gene.  The  thin  bar  designates  sequences 
of the genomic sequence  not  found in 4C 
mRNA. The lightly shaded boxes desig- 
nate non-coding sequences and  the  darker 
shaded boxes designate coding sequences. 
The start codon (AT'G) and stoo codon 
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(TGA) of the cDNA are indicate; along 




paper chromatography as described previously for (-)-pindolo1 (35). 
Membranes from transiently  transfected COS cells were  prepared by 
hypotonic lysis  in 1 mM HEPES,  pH 7.4, and  centrifugation a t  20,000 x 
g for 10  min at  4 "C. Membranes  were  resuspended  in 250 mM sucrose, 
5 mM MgCl,, 20 mM HEPES,  pH 7.5, and  stored  at -80 "C until  use. 
Binding  assays  with ['z511CYP were carried  out at  30 "C essentially as 
described previously (35) .  Nonspecific binding  was  determined in the 
presence of 10 PM propranolol. Competition binding  assays  contained 
120-150 PM ['251]CYP and  the indicated  concentrations of p-AR ligands. 
Each  experiment  was  repeated at  least  three  times  with  triplicate de- 
terminations.  The Kd of  ['z511CYl' was  obtained by Scatchard  analysis of 
saturation  binding  data.  The K, values of the  other P-AR ligands from 
competition  binding  assays  were  calculated according to the method of 
Cheng  and Prusoff (36). 
Cyclic AMP Accumulatio~z-Mouse L cells transfected with either 
pcDNA3 or pcDNA3-4C were plated a t  a  density of 2 x lo4 cells/cm2 in 
12-well tissue  culture  dishes.  After 72 h,  the cells were  labeled  with  2 
pCi of [3Hladenine/well in  a 37 "C  CO, incubator for 2  h.  The cells were 
washed twice, incubated  with 200 p~ IBMX for 20 min,  and  then  stimu- 
lated with the indicated concentrations of (-)-isoproterenol, (-)-epi- 
nephrine, or (-)-norepinephrine for 10 min.  In some experiments,  the 
incubation  medium  contained 0.2 PM (-)-propranolol  in  addition  to ago- 
nist.  The  reaction  was  terminated by aspirating  the  medium  and im- 
mediately  adding 1 ml of ice-cold 5% trichloroacetic acid with  0.1 mM 
cyclic AMP. L3H1ATP and [3Hlcyclic AMP fractions  were  separated on 
Dowex  50-X8 and  alumina columns as described previously (37). 
Inositol  Phosphate Accumulation-Inositol phosphate  accumulation 
was  measured  in  [3Hlinositol-prelabeled cells as described previously 
(38). Briefly, cells were  labeled  overnight  with 1 pCi of [3H]inositol/well, 
washed twice, and  incubated 10 min in medium  containing  10 mM LiC1. 
The cells were  stimulated  with  the  indicated  concentrations of drugs  in 
medium for 20 min,  the medium  was  aspirated,  and 1 ml of  5% trichlo- 
roacetic acid was  added.  This  solution  was  extracted  three  times  with 
ethyl ether, and inositol phosphates were isolated over Dowex 1-X8 
colums as described previously (39). 
RESULTS 
In a search for new G protein-coupled receptors, reverse- 
transcribed total RNA from fetal  turkey blood was amplified by 
PCR using  the TM  I11 and TM  VI primers described by Libert 
et al. (29). The resulting cDNA fragments were subcloned and 
sequenced, and five different clones with homology to  G pro- 
tein-coupled receptors were isolated. Two of these clones ap- 
peared to belong to the P - A R  family. One of them, 3C, showed 
high homology ( S O % )  to mammalian P,-ARs and likely repre- 
sents  the  turkey homologue of this subtype.' The other clone, 
X. Chen, J. L. Boyer, N. Young, T. K. Harden  and R. A. Nicholas, 
unpublished  experiments. 
'\\ ,' 68 '.,,' I . ,  
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designated 4C, displayed 50-60%  homology with all of the dif- 
ferent subtypes of p-ARs within the amplified region. Thus, 4C 
appeared to represent a novel subtype of  P-AR. 
Initial  attempts  to isolate  full-length cDNAencoding 4C from 
fetal  turkey blood or turkey  lung cDNA libraries were unsuc- 
cessful. These studies were initiated at a time  when the genes 
encoding p-ARs were thought to  be intronless (6, 16). We there- 
fore anticipated that  the full coding sequence could be identi- 
fied from genomic DNA. A Southern blot of turkey genomic 
DNA was screened at  high stringency with labeled 4C PCR 
probe, and  this  analysis revealed a  distinct  hybridization pat- 
tern indicative of a single gene (data not shown). A turkey 
genomic library  in A-DASH I1 was constructed and screened 
with a radiolabeled 4C PCR fragment. Numerous positive 
plaques were identified, and five of these were plaque-purified 
for further analysis. Southern blots of restricted  phage DNA 
indicated that four of the five phage contained a common 3.5-kb 
HindIII  fragment  that hybridized with the 4C PCR probe. A 
band of identical size also was observed on a Southern blot of 
HindIII-restricted genomic DNA. The  HindIII  fragment from 
one of these clones was subcloned and sequenced, and revealed 
a translational open reading  frame of 416 amino acids that was 
approximately 50% homologous to other p - A R  subtypes. 
Genomic Organization of the 4C Gene-During the course of 
this work, it was reported that both the  human  and  rat P,-ARs, 
unlike PI- and P,-ARs, were interrupted  in  their protein coding 
regions by an  intron (19-21). Rat P , - A R  was found to contain 
two introns  in  its genomic sequence,  whereas the  human P,-AR 
contained  a single intron  that  interrupted  the coding sequence. 
The open reading frames of the genomic sequences of both 
human  and  rat P,-ARs ended in GTAG, in which the TAG was 
an  apparent stop codon; in reality, GTAG was the 5' splice site 
of an  intron (19). Inspection of the genomic sequence of 4C 
revealed the sequence GTGA at  the end of the open reading 
frame, which suggested that 4C also might be interrupted by 
an  intron. To determine  whether  the 4C gene contained introns 
within its protein coding region, ribonuclease protection assays 
were initiated using lung mRNA (the  tissue  having  the  highest 
mRNA levels; see Fig. 4A) and  antisense RNA probes derived 
from various regions of the HindIII genomic fragment (Fig. 
lA). These  experiments  suggested that  the 4C gene contained 
at least one intron within the 3.5-kb HindIII  fragment  near  the 
3' end of the coding sequence. 
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1 AGCTTGTAAAAAAGCAGGCTCTGTTTTGCTAGCTCATGAATGGGAAGAAATGCCAACTGGATAATTTTTTACACATTTTCTTTCCTTCTTTGTCAACAT 
1 0 0  TCCCCCATTTGGCCGAAACTTCAAAATGCCATGCCATATTTGGAGAGCGCCCGTCTTAGAAGTTCCAGTATTTGTATAAATAGCTGATAGTGAAAAAATTGCCT 
2 9 8  TGGGCATCCTGGAGGATGGAGTCTGGGGATCCCAAAATTGCCAGCACTGACTCA~CTGAGGGGGTAGCAGTGCATGGCTACAGAAGCTGGGGAGAGGG 
1 9 9  GCCCTGGAGTCTGCCCAGGGGCCTTCGGAAGGAGCAGCAGCTCTGGGAACAGTGATGGACTCTGGGGCAGGGATGGGAGCAGCCCGGTGCCCCCCAACTCCC 
3 9 7  TTCAGGCATTAGATGTGGGGGTGAAAGAGCGGCGGCTGTTGG~~GATTTCTTTGGGGTGAGGCTGTCATTTTGCCATCCCTGTGCTGATGGCAGTCGGGTCA 
4 9 6  GTGTCTTCACTGCGTACCTGGAATGCGAGGAGCACAGAGGGAGCACGGAGCAAAGGGCTGGGATGCAGGGCAGGACGGACAGTAAGG~CGTGGAGAAT 
5 9 5  AAGGGCGGGTGGGGTGAGGGGCACAGTTGGGTCCGGC~'GCGCAGTGTCGGGGGTGTCCGGCCCGGGGGGCGGAGGGGAGGCGGTGCTCCCTCTCTGCTT 
6 9 4  T C A T T G A T C T C C G C A A A G G G G C A G C C C G G G G C C G C C C C G T T C C G A C G T C G G T G C A G C  
7 9 3  CTCGACGGCGGCGGCCGCCCCGAGCCCCGCTCCGGCCACGGGGAGCGCACGGGGGGC~GGAGTGCACGGAGCTGGACCGCCTCCCCCCGCCGAAGCG 
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8 9 2  ATG ACC  CG CTT  CCC GCA  GGC AAC GGC TCC  GTC  CT AAT TGC AGC TGG  CC  GCC GTT  CTG AGC CGG CAG TGG GCG 
M T P L P A G N G S V P N C S W A A V L S R Q W A 2 5  
9 6 7  GTG GGA GCC GCG CTG AGC ATC  ACC ATT  CTG  TC  ATC  GTG  CC GGC AAC CTG  CTG  TG  ATC  GTG  CA  TC  GCC AAG 
V G A A L S I T I L V l V A G N L L V I V A I A K 5 0  
1 0 4 2  ACG CCG CGG CTG CAG ACC ATG ACC AAC GTC  TTT  GTC ACC TCA  TTG  GCC  TGC  GCT  GAC  TC  GTC  ATG GGC TTG CTG 
T P R L Q T M T N V F V T S L A C A D L V M G L L 7 5  
1 1 1 7  GTG  TG  CCA  CCG GGG GCC  ACC  ATC  TG  CTG AGT GGT CAC TGG  CCC  TAC GGG ACG GTA  GTG  TGT GAG CTG  TGG ACC 
V V P P G A T I L L S G H W P Y G T V V C E L W T 1 0 0  
1 1 9 2   T C T  TTG GAC  GTG  CTG  TGC  GTG ACG GCG AGC ATC GAG  ACG CTG  TGC  GCC  ATC  GCC  GTG  AT CGC TAC  TG  CC  ATC 
S L D V L C V T A S I E T L C A I A V D R Y L A I 1 2 5  
1 2 6 7  ACG GCA  CCG  CTG CAG TAC GAG GCG CTG  TG ACC AAG GGC AGA GCG TGG GCT  GTG  TG  TGC ATG GTG  TGG  CC  ATC 
T A P L Q Y E A L V T K G R A W A V V C M V W A I 1 5 0  
1 3 4 2   T C T  GCC  TTC  ATC  TCC  TTC  CTG  CCC  ATC ATG AAC CAC TGG TGG CGG GAC GGG GCG  AC GAG CAG GCG GTG CGC TGT 
S A F I S F L P I M N H W W R D G A D E Q A V R C 1 7 5  
1 4 1 7  TAC  GAT  GAT  CCA CGC TGC  TGT GAC TTT  GTC ACC AAC ATG ACC TAC  GCC  ATC  GTC  TCC  TCC  ACC  GTC  TCC  TTC  TAC 
Y D D P R C C D F V T N M T Y A I V S S T V S F Y 2 0 0  
1 4 9 2  GTG  CCG  CTG  CTC  GTC ATG ATC TTT  GTC  TAC  GTC CGT GTC  TTT  GCT  GTG GCC  ACA CGC CAC GTC CAG CTC  ATC GGC 
V P L L V M I F V Y V R V F A V A T R H V Q L I G 2 2 5  
1 5 6 7  AAG GAT AAG GTG AGG TTC  TG CAG  AG  AAC CCC AGC CTC AGC TCC AGG GGC GGG CGG TGG  CGT CGG CCC  TCC CGC 
K D K V R F L Q E N P S L S S R G G R W R R P S R 2 5 0  
1 6 4 2  CTG  TTG  CC  ATC AAG GAG CAC AAG GCG CTC AAG ACC  TTG GGC ATC  ATC ATG GGC ACC TTC ACG CTC  TGC TGG  CTG 
L L A I K E H K A L K T L G I I M G T F T L C W L 2 7 5  
1 7 1 7  CCA  TTC  TTC  GTG  GCC AAC ATC  ATC AAG GTG TTC  TGC CGG CCG  CTG  TG  CCC  GAC CAG CTG  TTC  CTC  TTC  CTC AAT 
P F F V A N I I K V F C R P L V P D Q L F L F L N 3 0 0  
1 7 9 2  TGG TTG GGC TAC  GTC AAC TCA GCC TTC AAT CCC  ATC  ATC  TAC  TGC CGC AGC CCC GAC TTC AGG AGC GCT  TC CGC 
W L G Y V N S A F N P I I Y C R S P D F R S A F R . 3 2 5  
1 8 6 7  AAG CTG  CTG  TGC  TGC  CA  CGC  GT  GCC GAC CGC CGG CTG CAC GCT  GCC  CA CAG GAC  CA CAG CAC TGC  TCC  TGT 
K L L C C P R R A D R R L H A A P Q D P Q H C S C 3 5 0  
1 9 4 2  GCC  TTC AGC CCC CGG GGG GAT  CCC ATG GAG GAC AGC AAG GCT  GTG GAC CCC GGG CAT CTC AGG GAG GAC AGC GAG 
A F S P R G D P M E D S K A V D P G H L R E D S E 3 7 5  
2 0 1 7  GTG CAG GGG AGC GGC AGG  AGG GAG GAG AAT GCC TCA  TCC CAT  GGT  GGT GGC CAC CAG CAA CGG CCC  TG GGC GAG 
V Q G S G R R E E N A S S H G G G H Q Q R P L G E 4 0 0  
2 0 9 2  TGC  TGG  CTG CAG GGC ATG CAG AGC ATG CTG  TGC GAG  CAG CTG GAT GA 
C W L Q G M Q S M L C E Q L D E  
2 1 3 9  ~TGAGTACTGTGTGCATGCTTGGGGTGCAGGGTGCTTTTCTGGGGGACTGCTGGTGGTGGGGCTGCGGTCCGATGAATGC 
2 2 1 9  AGAGCTGGTGAGCAGGCATTCTCACTGGGATGGGGTATAGAATGGGAACTGCTGCCCAGCGCCTTTGGGGTTCCTTAAAC 
2 2 9 9  CCCTCTGCCAGGCTGCAGAGCTGAGGTTCTTAGTGCCCCCCCCGTCCCCATCTCACTTTGTCCCTTTCTGGGAGTGCCCC 
2 3 7 9  AACAACCAGAATGAGGTTCATTTCCTCAGGTAGTAAAACGCTACTGGGACGCCAGGAGTGTGTTCCTGTCCCTGGGATCT 
2 4 5 9  CCTCCCTTCTCACTCCCGATGACTTCAGGGAGCCCCTGCTGTTATGGGGATGGTGTGGGCTCTTCATACTCTATGCTCTC 
2 5 3 9   T C A T T T A a  
2 5 4 8  G  TTC ACC AGC ACA GAG ATG CCG GCG GGT  CCC  TCG  TC  TGA CTGGGAATGCAGCAGAGCAGGGAGCACT 
F T S T E M P A G P S V *  
4 1 6  
4 2 8  
2 6 1 6  ~AAGTGTGTGTTCTGCC~GGGAGCAGTGCCACAGGAGACTCCAGTGTGTGGCTGCAGCAGGGCCACCCCTGTCTCGGCA 
2 6 9 6  GCAGTCCCCTCTGACCAGCTTGGCTGTCCCCTTCCCTGGGGGAGCTCAGCCCTTGGCTGTGTCACATCGAGCATGTGAGC 
2 7 1 6  TGACGCAGGCGTCTGCTGACACGTTTCTGTGCTGCCCAGAGTGCTTAACCCCCTTCAGAGCAGTTTGCTCTGCAGTGCTT 
2 8 5 6  GCACGCTGCTGCTGAGGCCAGGACCCCCCTTTGCACTCTCCCCTTCCAGGGGCTCAGCTCCTGGAGTGGTTGCTTTGCAT 
2 9 3  6 CCTCAGTGTTGTGATGATGGGAGGATGCACACCATCAGCTCCTGCTATCTTCTTGCAG 
2 9 9 4  ATGTTGGGACGGGGATGCTGTGTGGGGAAGGAGGAGTGGCACTGAGGGGGACAACGCTGGAAGGACCCTCTGGTGCATGCACCCACACGGAGAGCAAAG 
3 0 9 3  AGGCTCCTCCGGTGCTGGAAAGATAAAGGCAGCAGCA~AAGATCCTGAGCCCCTCACGATGAGGTTCCATGCAGCAGCACAGCTTCTGGGGATGGAG 
3 1 9 2  ATGCTGCCACCCCAGAGGGATTGGAGCTGGGACATGGTGACCAGCAGCTCTGCTCGCCTGCAGGATCCCATCTTCCTGGGTTGTGTCGTTGGCAAAAGGGG 
3 3 9 0  AGAGAAAAGCACAGGCGGGAGAGGAGCCAGGGATAAAGAGAGTGCTGCAGGAGAAGCT 
3 2 9 1  AAAGA~GATCTCCTGCTGGCAAGAAACTGCTCCACGATCTGCACTGGGTCCTGCCCCAGGCACTGCAGTGAGCTCCTGGTGATGCTGGGAGCCACAGCA 
is shown. Introns are italicized and indented. The intron border consensus sites (GT/AG) are underlined. 



























FIG. 3. Alignment of the deduced amino acid sequences of the turkey 4C receptor,  human p,-, &-, and &-ARs, and the turkey p,-AR. 
Shaded  areas indicate  amino acid identity  to  the 4C receptor. The  putative  seven  transmembrane  helices  are  shown by the heavy  bar over the 
sequence.  Possible A'-linked glycosylation sites  are underlined. The hyphens indicate  gaps  introduced  to  improve  the  alignment.  Several  amino 
acids from the carboxyl terminus of &-AR have  not  been  included. 
To determine  the exact genomic organization of the 4C gene, 
oligonucleotide primers were  designed from sequences  within 
the putative seventh transmembrane segment and a region 
from the 3' end of the gene that  was shown to be protected from 
RNase digestion by 4C mRNA. These primers were used to 
amplify reverse-transcribed  lung RNA  by PCR, which resulted 
in  the amplification of a  single fragment of 575  bp that  was 
approximately 800 bp shorter than the fragment amplified 
from the genomic clone. It is important  to note that no other 
amplified fragments were observed after amplification by PCR, 
suggesting that alternative splicing does not occur for this 
gene. Subcloning and sequencing of the cDNA fragment delin- 
eated  the intron-exon  borders of the 4C gene, and revealed the 
genomic organization of the 4C receptor  (Figs.  1B and 2). Thus, 
the 4C gene is organized into a t  least three exons and two 
introns.  The  first exon is approximately 1380 bp long and en- 
codes the majority of the 4C amino acid sequence. The coding 
block is interrupted by an  intron of 409 bp  that contains con- 
sensus GT/AG splicing signals at  the  intron borders. This is 
followed  by a second exon of only 68 bp that encodes the  last 
twelve amino acids of the receptor. Another intron 378  bp in 
length  is  present  in  the 3' untranslated region that also con- 
tains  the consensus  splicing signals,  and a third exon follows 
and likely extends beyond the Hind111 site of the clone. This 
genomic organization is very similar  to  the  structure of the  rat 
&-AR gene, which also has  three exons and two introns.  The 
second exon in both rat &-AR and  turkey 4C is  68 bp in  length 
and encodes the  last 12  amino  acids of the receptor. Unlike the 
rat  receptor, the second exon of human &-AR is much longer 
and codes for only the  last 6  amino  acids  (21). 
Features of the Deduced Amino Acid Sequence of 4C-The  4C 
cDNA sequence  contains a translational open reading  frame of 
1284 bp that encodes a  protein of 428 amino  acids and a cal- 
culated  molecular  weight of 47,367 (Fig. 2). The  reading  frame 
begins with a methionine codon that is in the context of a 
reasonable but not  optimal translation  initiator consensus se- 
quence (40). Ribonuclease protection assays from the 5' end of 
TARLE I
Percent homologies in  p-adrenergic receptors 
The  percent homologies between  members of the p - A R  family  were 
calculated from optimal  alignments of each set of sequences.  The  align- 
ments for p,-AR, p,-AR, and p,-AR were derived using human se- 
quences.  The  values  in  each column were  calculated by dividing  the 
number of identical amino acids in each alignment set by the total 
number of amino  acids  in  the p - A R  in  the column. 
p - m  p4c-m PI-" p2-m P 3 - m  Pt-m 
(428)"  (477)  (413)  (408)  (483) 
% 
P,,-AR 48 46 53 46 
p1-m 54 51  52  59 
p2-m 44  44 41  41 
p3-m 50  45 40 38 
P,-AR 51 60 47  45 
Number of amino acids. 
the gene  indicated that  the mRNAbegins  approximately 100 bp 
before the proposed initiator ATG codon (data not shown). 
Kyte-Doolittle (41)  hydropathy  analysis of the deduced amino 
acid sequence of  4C predicts the presence of seven hydrophobic 
regions that presumably correspond to the seven putative 
transmembrane  segments (TM1-TM7) that  are  the  hallmarks 
of G protein-coupled receptors (42,43). Two potential  N-linked 
glycosylation sites  are  present  in  the extracellular  amino  ter- 
minus  and one potential site  is found in a putative extracellular 
position just prior to TM5. The 4C sequence includes the two 
serine  residues  in TM5 (Ser-204 and Ser-207 of p2-AR) that  are 
thought  to form hydrogen bonds with catechol hydroxyl groups 
(44, 451, two aspartic acid residues (corresponding to Asp-79 
and Asp-113 of the p2-AR sequence) that  are  thought  to be 
involved in agonist stimulation  and catecholamine binding, re- 
spectively (461, and  three cysteine  residues in  the  putative sec- 
ond extracellular loop that  are  thought  to f rm disulfide bonds 
and  to play  a role in ligand  binding (47,48). A  potential protein 
kinase A  phosphorylation site (RRPS; residues 246-249) that  is 
thought  to be important  in heterologous desensitization is also 
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FIG. 4. Tissue distribution and Northern blot analysis of 4C 
mRNA. Panel A, the  tissue  distribution of  4C mRNAwas  determined by 
ribonuclease protection analysis using antisense 4C PCR fragment 
cRNA as a probe. Fifty pg of total RNA were  used  with the exception of 
brain RNA, where 25 pg were  used. Bl, blood; Lu, lung; Br, brain; GI, 
gastrointestinal  tract; H, heart; K, kidney; L, liver; SM, skeletal  muscle; 
and St ,  stomach.  The arrow indicates  the  protected  fragment. Panel B ,  
Northern blot analysis of lung mRNA. Two different  amounts of lung 
mRNA were loaded onto a formamide agarose gel and probed with 
antisense  4C cRNA. The mobility of RNA standards  run on the  same gel 
are indicated on the side of the blot. 
present  in  the  putative  third  intracellular loop. 
Homology to the four other p-ARs (human p,-AR, p,-AR, 
p,-AR, and  turkey &-AR) clearly indicates  that 4C belongs to 
the p-AR family (Fig. 3). Almost all of this homology occurs in 
the  putative  transmembrane  segments,  with  the exception of 
TM1. Likewise, there is very little homology between these 
receptors in the amino and carboxyl-terminal regions and 
within the  third  intracellular loop. The  percent homologies be- 
tween  different subtypes were  calculated from optimal align- 
ments of each set of p - A R  sequences and  are  presented  in Table 
I. The 4C receptor  displays  between 44% to 54%  homology with 
all of the  other p-ARs, with  the  highest homology occurring 
with p,-AR and  the lowest homology with p,-AR. Although the 
genomic organization of 4C is  similar  to  that of p,-AR, the 
homology between these two receptors was  about  the  same as 
the homology between p,-AR and p,-AR, which are clearly sepa- 
rate  subtypes of p-ARs. Despite the  fact  that &-AR and  the 4C 
receptor were from the same species, the two avian P-ARs 
appeared  to be no more homologous to  each  other  than  to  the 
mammalian p-ARs. These  data strongly suggest  that 4C rep- 
resents a novel subtype of p-AR.  This  idea is supported by the 
>80% homology observed between the meleagrid (turkey) 
p,-AR and  mammalian pz-AR.2 
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COS-1 cells transiently transfected with turkey 4C cDNA. In- 
FIG. 5. Binding of ['mI]CYP to membranes prepared from 
creasing  concentrations of ['*'11CYP were  incubated  with  membranes 
from 4C-transfected cells a t  30 "C and specific binding  was  determined 
as  described  under  "Experimental Procedures." The inset shows a plot of 
the  data  transformed  according to the method of Scatchard.  The Kd of 
['*'I]CYP calculated from these  data  was 70 PM, and  the B,,, was 819 
fmoVmg  of protein. 
Tissue Distribution of 4C mRNA-The tissue distribution of 
turkey 4C 0-AR mRNA was examined by ribonuclease protec- 
tion analysis (Fig. 4)  using  antisense RNA prepared from the 
original PCR-amplified 4C clone as a probe. 4C mRNA was 
widely expressed, with  the  highest levels found in lung. Other 
tissues expressing  high  levels of message  were  (in  descending 
order) blood, intestine, stomach, heart, and brain. Northern 
blot analysis of lung mRNA hybridized with the  same RNA 
probe revealed a major band around 2.8 kb. Several higher 
molecular  weight bands also  were observed, most notably at 5 
kb; these may represent  either  immature mRNAs containing 
intron sequences or mRNAs with  different  lengths of the poly- 
adenylation  tail.  A similar  pattern of bands on a Northern blot 
also was reported for p,-AR. 
4C cDNA Encodes a p-AR with a Unique Pharmacological 
Selectivity-To further  demonstrate  that 4C represents a mem- 
ber of the p-AR family, full-length cDNA encoding 4C was 
cloned into  the expression vector pcDNA3 and  transiently ex- 
pressed in COS-1 cells. Expression of  4C receptor in  these cells 
was assessed in membrane preparations from vector-trans- 
fected and 4C-transfected cells with the high affinity P - A R  
ligand [12sI]CYP. COS-1 cells natively  express a low level (19 
fmoVmg protein) of simian p,-AR, and no difference in the 
levels of [12sI]CYP binding was observed in  membranes from 
native  and vector-transfected COS-1 cells. However, the level of 
['251]CYJ? binding was approximately 40-fold higher (819 
fmoVmg protein)  in  membranes from 4C-transfected cells than 
was observed with membranes from control or vector-trans- 
fected cells. Because of the high level of expression of the 4C 
receptor in transfected cells, dilution of the membranes to give 
an  optimal level of  [12sI]CYP binding to  the 4C receptor lowered 
the binding of ligand to endogenous p,-AR to essentially  unde- 
tectable levels. Thus, the pharmacological selectivity deter- 
mined by  [12sI]CYP binding in transfected COS-1 cells repre- 
sents  that of the 4C p-AR receptor. 
[1251]CYP bound to  membranes prepared from 4C-transfected 
cells with a Kd of 70 PM (Fig. 5, Table 11). In  contrast,  the K d  
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TABLE I1 
Apparent  afinities of a series of p - A R  agonists  and  antagonists 
Values for 4C were  calculated from either  saturation  binding  analysis or competition  binding  experiments as described  under  "Experimental 
Procedures."  Other  values  were  obtained from the  literature  (references  in  parentheses) from either  human  (PI-, &-, and P,-ARs) or  turkey (&-AR) 

















3200 -c 120 
140 * 61 
530 f 42 
820 2 380 
0.07 _+ 0.01 
3.9 * 2.3 
1.0 2 0.45 
8.0 _+ 3.7 
16 * 3 
400 _+ 130 
83 * 33 
830 * 60 
4500 t 300 
5600 -c 1900 
100 (51)" 241 (51)" 3900 (52)" 
973 (51)" 15440 (51)" 13000 (52)" 
1120 (51)" 1035 (51)" 40000  (52)" 









2.3 (54)= 11 (16)" 
0.7 (54)" 145 (54)" 
1.5 (54)" 70 (16)" 
















Determined  with  recombinant  receptors. 
Determined  in  human  fat  membranes. 
Determined in  human  heart  membranes. 
Determined  in  human  cerebral  arteries. 
e Determined  in  turkey  erythrocyte  membranes. 
values for ['251]CYP at the endogenous &-AR on COS-1  cells 
and &-AR on turkey erythrocytes were determined  to  be  10 PM 
and 5 PM, respectively (Table 11). Thus, the 4C receptor dis- 
played an  intermediate affinity for [1251]CYF', which was lower 
than  that for &-AR (17 PM), p2-AR, or &-AR, but much  higher 
than  the affinity  reported for human &-AR (230 PM) (Table 11). 
Analysis of the  apparent binding  affinities of several p-AR 
agonists  and  antagonists  indicated  that  the pharmacological 
selectivity of 4C is unique  and does not  match  any of the  other 
cloned p-ARs. The 0-AR agonists (-)-isoproterenol, (-)-norepi- 
nephrine,  and (-)-epinephrine  inhibited ['251]CYP binding with 
relatively  high  affinity (Table 11). The classical p-AR antagonist 
(-)-propranolol inhibited [1251]CYF' binding with high affinity 
(K, - 1 nM), whereas  the affinities of IC1 118551 (K, - 83 nM) 
and metoprolol (K, = 4.5 PM) were  relatively low (Fig. 6, Table 
11) and did  not match  their reported relative affinities for p2-AR 
and p,-AR, respectively. Other 8-AR antagonists also  inhibited 
['251]CYP binding  to  the 4C receptor (Table 11). However, the 
affinities and overall rank  order of potencies of these antago- 
nists did  not closely match  that previously reported for any of 
the B - A R  subtypes. 
4C Receptors Are Functional and Activate  Adenylyl Cyclase 
in Mouse L Cells-Mouse L cells, which do not express endog- 
enous S-AR, were transfected with 4C receptor cDNAto test  the 
second messenger signaling  properties of the receptor. Several 
stable clonal cell lines expressing  different levels (9-39 fmol/mg 
of protein) of  4C receptors  were assayed for the production of 
second messengers following receptor  activation. Stimulation 
of cells expressing the 4C receptor  with either (-)-isoproterenol, 
(-)-norepinephrine, or (-)-epinephrine resulted  in  an  increase 
in  the accumulation of intracellular cyclic  AMP (Fig. 7A).  The 
fold stimulation above basal  appeared  to correspond to  the level 
of 4C receptor  expression,  with the highest levels of cyclic  AMP 
accumulation  occurring in cells expressing the  highest level of 
4C receptors (clone S4; 39 fmol/mg protein). The maximal level 
of  cyclic AMP accumulation  occurring in response to (-)-isopro- 
terenol  was  very similar  to  that observed with activation of the 
natively  expressed prostaglandin E, receptor by maximally ef- 
fective concentrations of prostaglandin E, (data  not shown). 
Stimulation of 4C-transfected cells with (-)-norepinephrine 
and (-)-epinephrine resulted  in  increases in the levels of cyclic 
AMP accumulation with values of approximately 2.5 and  10 
60 
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FIG. 6. Inhibition of binding of ['asIICYP to 4C-transfected 
membranes by p-AR antagonists. [12511CYE' binding assays were 
performed  in  the  presence of the  indicated  concentrations of several 
&-AR or &-AR selective  antagonists.  The  calculated K, values of pro- 
pranolol  (non-selective), IC1 89406 (pl-selective), IC1 118551 (p,-selec- 
tive), and metoprolol (&-selective)  were 1 m, 16 MI, 83 MI, and 4.5 p, 
respectively. 
nM, respectively (Fig. 7A). (-)-Isoproterenol stimulated cyclic 
AMP accumulation with high potency = 0.4 nM; Fig. 7A), 
and  in  the presence of 0.2 PM (-)-propranolol the concentration- 
effect curve was shifted to the  right by approximately 2.5 log 
units,  suggesting  that propranolol is a competitive antagonist 
at   the 4C receptor  (Fig. 7B) .  (-)-Isoproterenol had no effect on 
cyclic  AMP levels in vector-transfected cell lines. 
It  has been reported  (49,591 that  stimulation of turkey  eryth- 
rocyte membranes with (-)-isoproterenol activated phospho- 
lipase C in addition to  activating adenylyl cyclase. Since tissue 
distribution studies indicated that  the 4C receptor, in addition 
to Pt-AR, was present on blood cells, we examined whether 
activation of phospholipase C occurred through  stimulation of 
the 4C receptor. Stimulation of cells expressing the 4C receptor 
with (-)-isoproterenol did not  result  in inositol lipid hydrolysis, 
whereas stimulation of these same cells with ATP acting 
through a  natively  expressed P,-purinergic receptor resulted 
in the marked accumulation of inositol phosphates (Fig. 8). 
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FIG. 7. Agonist-stimulated  cyclic AMP accumulation  in  mouse 
L cells  expressing  the 4C receptor. Panel A, accumulation of cyclic 
AMP in 4C-transfected mouse L cells in response to p-AR agonists. 
Mouse L cells transfected with 4C cDNA were labeled with r3H1adenine 
for 2 h, preincubated with IBMX, and then stimulated with the indi- 
cated amounts of (-)-isoproterenol (ISO, m), (-)-norepinephrine (NOR, 
O), or (-)-epinephrine (EPZ, A) for 10 min. Cyclic  AMP and ATP levels 
were determined as described under "Experimental Procedures," and 
the  data  are plotted as the percent conversion of ATP to  cyclic AMP. 
Panel B,  the effect of propranolol on the response of 4C-transfected 
mouse L cells to  (-)-isoproterenol. Transfected cells labeled with 
L3H]adenine as described above were stimulated with the indicated 
concentrations of (-)-isoproterenol either in  the absence (m) or in the 
presence (0) of 200 n~ propranolol for 10 min. This experiment was 
repeated three times with similar results. 
These data suggest that 4C, like other cloned p-ARs, couples 
solely to the activation of adenylyl cyclase in mouse L cells and 
not to the activation of phospholipase C. 
DISCUSSION 
Our data describe the molecular cloning, expression, and 
characterization of a novel P - A R .  Comparison of the deduced 
amino acid sequence of 4C to other p-ARs  revealed that 4C 
shared 4654% homology with other cloned P-ARs, which falls 
in  the range of homologies observed among the other p - A R  
subtypes. When expressed transiently  in COS-1  cells, the 4C 
receptor bound the p - A R  ligand [1261]CYP with high affinity. 
The relative binding affinities of a series of agonists and  an- 
tagonists suggest that  the 4C receptor displays a unique phar- 
macological selectivity that  is distinct from other p-ARs. Acti- 
vation of 4C receptors stably expressed in mouse L cells 
resulted in  the accumulation of cyclic AMP, which indicates 
l 2 1  10 
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FIG. 8. Phospholipase C activation  in mouse L cells expressing 
the 4C receptor. Mouse L cells transfected with 4C cDNAwere  labeled 
with [3H]inositol overnight, washed, and incubated in 10 mM LiCl  for 10 
min. The cells  were stimulated for 20 min with the indicated concen- 
trations of (-)-isoproterenol (m, ISO)  or ATP (A), and inositol phos- 
phates were determined as described under 'Experimental Proce- 
dures." This experiment was repeated twice with similar results. 
that  this receptor, like other P-ARs, couples to  the adenylyl 
cyclase  pathway. 
Ribonuclease protection assays at the 5' end of the gene 
suggested that 4C  mRNA begins approximately 100 bases up- 
stream of the putative ATG start codon. Although we cannot 
unambiguously conclude that another exon  does not exist far- 
ther  upstream of the gene that would extend the amino termi- 
nus,  this  is unlikely. The amino terminus, although the small- 
est of the p-ARs, contains two consensus glycosylation sites,  the 
same number found in  the  three mammalian P-ARs. Further- 
more, there is no precedent for a splicing event at this end of a 
p - A R  gene, and expression of 4C receptors from the putative 
start codon resulted in high levels of functional receptors. 
The data presented here on the 4C receptor gene add useful 
new information on the genomic organization of P-ARs. The 
genomic organization of 4C at the 3' end of the gene was de- 
termined by comparing the genomic  sequence with a cDNAclone 
obtained by amplification by  PCR. There are two introns in  this 
region,  one ofwhich interrupts  the protein coding  sequence. The 
second  exon,  which isonly 68 bp,  encodes the  last 12 amino  acids 
of the 4C receptor,  while the second intron  is within the 3' un- 
translated region of the gene. This genomic organization is very 
similar to that of the  rat &-AR gene in that  the second  exons of 
both the turkey 4C gene and the  rat p,-AR genes are 68 bp and 
encode the  last 12 amino acids ofthe proteins. The human p,-AR 
gene,  however, has only  one intron and the second  exon  encodes 
the  last six amino acids of the receptor. 
The similarity between the genomic organizations of the 
avian 4C and rat @,-AR genes suggests that they may have 
originated from the same ancestor. However, the 4C receptor is 
not the  turkey equivalent of mammalian p,-AR. That  is,  its 
amino acid sequence is not more  closely related to p,-AR than 
to  &-AR or p,-AR. In fact, by these criteria, 4C would appear to 
be closer to &-AR than to any of the other p-ARs. Moreover, the 
order of potencies of a series of agonists and antagonists for the 
4C receptor markedly differ  from those previously reported for 
mammalian p,-AR (Table 11). 
In addition to p,-AR and  the avian 4C receptor, the p i A R  has 
an intron within its protein coding ~equence.~ Furthermore, 
E. Ross, personal communication. 
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Machida et al. (4) noted that  the continuous homology between 
the  human  and  rat @,-AR genes is  interrupted by a 99-bp seg- 
ment  that begins  with the  same sequence  found at the begin- 
ning of the  first  intron of both the  rat  and  human p,-AR (GTAG) 
and  ends with a consensus 3' donor splice signal, which sug- 
gests  that  this  element was at one time  an  intron. Comparison 
of the rat genomic sequence of p,-AR to  its cDNA sequence 
indicated that  this possible splicing  signal is not  used in  rat 
(19). A similar story emerges in  the &-AR genes from rat  and 
human. Analysis of the  intron sequence in the  human gene 
indicated that  it  contains 5' and 3' splicing signals a t  similar 
positions as found in  the  small second exon of the  rat gene, but 
these signals are not used during maturation of the mRNA 
strand (21). The  authors  suggested  that  the splicing event  may 
be species dependent. 
The  relative potencies of a series of p - A R  agonists and  an- 
tagonists in inhibiting [1251]CYF' binding to the 4C receptor 
indicated that  its pharmacological selectivity  was unique  and 
did not closely match any of the  other @ - M s .  For example, 
(-)-epinephrine and (-)-norepinephrine displaced [1251]CYP 
from the 4C receptor with very similar and relatively high 
affinities (Table 11), which would make 4C more like p,-AR than 
any of the  other p-ARs. However, the P,-specific antagonists 
IC1 89406 and metoprolol showed much lower affinity at 4C 
receptors than  their reported  affinities a t  p,-AR. Likewise, the 
@,-specific antagonist IC1 118551  exhibited a much lower affin- 
ity at  4C receptors than at &AR. Thus, the pharmacological 
selectivity of the 4C receptor does not  match  any of the  other 
@-AR receptors  in the  rank order of potency of several 8-AR 
antagonists. These data suggest that 4C represents a novel 
subtype of p - A R ,  which is consistent  with its amino acid se- 
quence homology to other @-ARs. However, a more extensive 
pharmacological analysis of the 4C receptor will be necessary to 
more  clearly define its  uniqueness  as  receptor that recognizes 
p-AR ligands. 
Activation of the 4C receptor  expressed in mouse L cells with 
(-)-isoproterenol, (-)-epinephrine, or (-)-norepinephrine  re- 
sulted in a concentration-dependent increase in the level of 
cyclic  AMP accumulation.  This suggests  that 4C couples to  the 
activation of adenyIy1 cyclase in vivo. However,  Rooney et aL. 
(49) and Vaziri and Downes (59) observed that  in addition to 
activation of adenylyl cyclase a marked activation of phospho- 
lipase C occurred upon stimulation of turkey erythrocyte  mem- 
branes with (-)-isoproterenol. At maximal concentrations of 
(-)-isoproterenol, stimulation of phospholipase  C was 3040% 
of the level observed with a maximally effective concentration 
of the P,-purinergic receptor  agonist, ADPPS. @,AR is likely 
the major @ - A R  on turkey erythrocytes (261, but  the  present 
study  indicates  that 4C mRNA is also present  in  fetal blood 
cells. Thus, 4C receptors could contribute to the isoproterenol- 
stimulated inositol  lipid  hydrolysis in  turkey erythrocytes, par- 
ticularly since &ARs do not couple to phospholipase  C in mam- 
malian cells even when expressed at high levels (50). However, 
isoproterenol stimulation of mouse L cells expressing the 4C 
receptor did not evoke an increase  in  phosphoinositide hydrol- 
ysis, suggesting  that  the 4C receptor does not couple to  this 
pathway in these cells. 
One  question that  arises from this work is  whether  the 4C 
receptor is  an  avian specific 0-AR subtype or represents a novel 
0-AR subtype  that also exists  in  mammals. Because birds  and 
mammals  separated relatively early  during evolution, it  is  en- 
tirely possible that  birds developed a different set of p-AR sub- 
types from mammals. The fact that a mammalian  counterpart 
of &-AR has not been identified to date supports this idea. 
However, several  lines of evidence also suggest  that  birds  are 
not far removed from mammals  in  terms of signaling proteins. 
For example, another p-AR PCR clone (3C) was isolated from 
turkey blood  RNA that displayed over 80% homology to  human 
p2-AR.' This  result strongly suggests  that  this clone represents 
the avian homologue of mammalian p2-AR, which indicates 
that  birds have at least one member of the @ - A R  family in 
common with mammals. The guanine nucleotide regulatory 
protein Gall  has been cloned and sequenced from turkey, and it 
is over 96% homologous to human Gall (30). A partial clone of 
turkey phospholipase C-pl also indicates high homology 
(>go%) with the  mammalian forms of this  i~oenzyme.~ Because 
it is unclear whether all of the atypical responses to 0-AR 
agonists can be accounted for by &-AR, additional mammalian 
8-AR subtypes may  exist. We are  currently  pursuing identifi- 
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